49 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
34
Selective inhibitors of protein methyltransferases.
Icahn School Of Medicine At Mount Sinai
25
Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8.
University of North Carolina at Chapel Hill
5
Analogues of the Natural Product Sinefungin as Inhibitors of EHMT1 and EHMT2.
University of Copenhagen
12
Selective non-nucleoside inhibitors of human DNA methyltransferases active in cancer including in cancer stem cells.
Sapienza University of Rome
16
Discovery and development of potent and selective inhibitors of histone methyltransferase g9a.
Abbvie
47
Exploiting an allosteric binding site of PRMT3 yields potent and selective inhibitors.
University of North Carolina at Chapel Hill
21
Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.
University of North Carolina at Chapel Hill
3
Chemical probes for histone-modifying enzymes.
Johns Hopkins University School of Medicine
37
Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines.
University of North Carolina at Chapel Hill
14
Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a.
University of North Carolina
25
Discovery of Highly Potent and Selective EZH2 Covalent Inhibitors via Incorporating Basic Amines.
Sun Yat-Sen University
1
Harnessing the SPOP E3 Ubiquitin Ligase via a Bridged Proteolysis Targeting Chimera (PROTAC) Strategy for Targeted Protein Degradation.
Icahn School Of Medicine At Mount Sinai
23
Current and Emerging Approaches Targeting G9a for the Treatment of Various Diseases.
Sichuan University
32
One stone two birds: Introducing piperazine into a series of nucleoside derivatives as potent and selective PRMT5 inhibitors.
Ocean University of China
1
Frequent upregulation of G9a promotes RelB-dependent proliferation and survival in multiple myeloma.
National University of Singapore
11
An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.
UNC Eshelman School of Pharmacy
10
Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation.
Epizyme, Inc.
2
Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.
Daiichi Sankyo Co., Ltd
1
Discovery of novel G9a/GLP covalent inhibitors for the treatment of triple-negative breast cancer.
Sichuan University
40
Discovery of a Highly Potent and Selective Inhibitor Targeting Protein Lysine Methyltransferase NSD2.
Sun Yat-Sen University
31
Discovery of a Highly Potent Lysine Methyltransferases G9a/NSD2 Dual Inhibitor to Treat Solid Tumors.
Sun Yat-Sen University
18
Discovery of a Potent, Selective, and Cell-Active SPIN1 Inhibitor.
Icahn School Of Medicine At Mount Sinai
11
SETDB1 as a cancer target: challenges and perspectives in drug design.
University of Sao Paulo
2
Discovery of Potent and Selective G9a Degraders for the Treatment of Pancreatic Cancer.
Shanghai Institute of Materia Medica
18
NSD3: Advances in cancer therapeutic potential and inhibitors research.
Peking University
33
Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2).
University of Texas Medical Branch (UTMB)
26
Structure-Based Discovery of Inhibitors of the SARS-CoV-2 Nsp14 N7-Methyltransferase.
University of California San Francisco
27
Structure-Based Design and Characterization of the Highly Potent and Selective Covalent Inhibitors Targeting the Lysine Methyltransferases G9a/GLP.
Sun Yat-Sen University
17
Discovery of a New-Generation S-Adenosylmethionine-Noncompetitive Covalent Inhibitor Targeting the Lysine Methyltransferase Enhancer of Zeste Homologue 2.
Sun Yat-Sen University
16
Discovery of cysteine-targeting covalent histone methyltransferase inhibitors.
Nanjing Medical University
63
Discovery of Novel Substrate-Competitive Lysine Methyltransferase G9a Inhibitors as Anticancer Agents.
Kyorin Pharmaceutical
10
Quinazoline-based hydroxamic acid derivatives as dual histone methylation and deacetylation inhibitors for potential anticancer agents.
Tsinghua University
61
Fascinating Transformation of SAM-Competitive Protein Methyltransferase Inhibitors from Nucleoside Analogues to Non-Nucleoside Analogues.
Csir-Indian Institute of Chemical Biology
4
Discovery of the First-in-Class G9a/GLP Covalent Inhibitors.
Icahn School Of Medicine At Mount Sinai
21
Identification and in vitro characterization of a new series of potent and highly selective G9a inhibitors as novel anti-fibroadipogenic agents.
Promidis
19
Discovery of novel histone lysine methyltransferase G9a/GLP (EHMT2/1) inhibitors: Design, synthesis, and structure-activity relationships of 2,4-diamino-6-methylpyrimidines.
Daiichi Sankyo
9
Discovery of a Novel Chemotype of Histone Lysine Methyltransferase EHMT1/2 (GLP/G9a) Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Co-crystal Structure.
The University of Texas M.D. Anderson Cancer Center
27
Discovery of Potent and Selective Inhibitors for G9a-Like Protein (GLP) Lysine Methyltransferase.
Icahn School Of Medicine At Mount Sinai
47
Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces.
Wuxi Apptec (Tianjin) Co.
19
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
Radboud University
33
Methyllysine binding domains: Structural insight and small molecule probe development.
University of Connecticut
39
Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy.
Universidad De Oviedo-Principado De Asturias
29
Structure-activity relationship studies of G9a-like protein (GLP) inhibitors.
Icahn School Of Medicine At Mount Sinai